Trastuzumab deruxtecan given conditional approval in EU for HER2-positive breast cancer

Approval is specifically for unresectable or metastatic HER2-positive breast cancer in patients who have received two or more prior anti-HER2-based regimens. Approval is based on results from the DESTINY-Breast01 Phase II trial which found an objective response rate of 61.4%.

PharmaTimes